Cargando…
Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of people and caused tremendous morbidity and mortality worldwide. Effective treatment for coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 infection is lacking, and different therapeutic strate...
Autores principales: | Lu, Ligong, Zhang, Hui, Zhan, Meixiao, Jiang, Jun, Yin, Hua, Dauphars, Danielle J., Li, Shi-You, Li, Yong, He, You-Wen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Science China Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756132/ https://www.ncbi.nlm.nih.gov/pubmed/33355886 http://dx.doi.org/10.1007/s11427-020-1859-y |
Ejemplares similares
-
Preventing Mortality in COVID-19 Patients: Which Cytokine to Target in a Raging Storm?
por: Lu, Ligong, et al.
Publicado: (2020) -
Clinically approved combination immunotherapy: Current status, limitations, and future perspective
por: Lu, Ligong, et al.
Publicado: (2022) -
A Potential Role of Interleukin 10 in COVID-19 Pathogenesis
por: Lu, Ligong, et al.
Publicado: (2021) -
miR-125b-5p inhibits cell proliferation, migration, and invasion in hepatocellular carcinoma via targeting TXNRD1
por: Hua, Shengni, et al.
Publicado: (2019) -
Opportunities and challenges of patient-derived models in cancer research: patient-derived xenografts, patient-derived organoid and patient-derived cells
por: Hou, Xiaoying, et al.
Publicado: (2022)